Drug Discovery Today

DECEMBER 17, 2019

December 10, 2019 — Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products, today announced that it has completed clinical production of Bridge Therapeutics Inc.’s Somerset, N.J. Birmingham, Ala.–

Production 100

Production Licensing Licensing Treatment 100

Drug Target Review

DECEMBER 9, 2024

Baker’s model could revolutionise drug development, synthetic biology, and nanotechnology, opening possibilities for new medical treatments, vaccines, nanomaterials, and sensors. The Rosetta algorithm has been incorporated into AI-powered tools like RoseTTAfold, which uses a three-track neural network to predict protein structures.

Engineering 105

Engineering International Drug Development Science 105

Broad Institute

JULY 10, 2024

A three-drug cocktail known as Trikafta has greatly improved patient quality of life since its development in 2019, but can cause cataracts and liver damage and must be taken daily at a cost of about $300,000 per year. With further development, it could pave the way for treatments that are administered only once and have fewer side effects.

Engineering 145

Engineering Packaging DNA Treatment 145

Common Sense for Drug Policy Blog

MAY 8, 2024

Regardless of region, jail jurisdiction size, locality, or opioid overdose death rate, larger percentages of jail jurisdictions initiated behavioral or psychological treatment for OUD than initiated or continued MAT. Opioid Use Disorder Screening and Treatment in Local Jails, 2019. In states with 24.0 Maruschak, Todd D.

Treatment 52

Treatment 52

SCIENMAG: Medicine & Health

JUNE 8, 2023

Statement Highlights: A new American Heart Association scientific statement focuses on treatment strategies for pediatric cardiomyopathy (diseases of the heart muscle’s structure and function that may lead to heart failure and death) and is a companion to a 2019 scientific statement focused on diagnosis of the condition.

Treatment 61

Treatment Disease 61

Common Sense for Drug Policy Blog

MAY 8, 2024

Opioid Use Disorder Screening and Treatment in Local Jails in the US "At midyear 2019, fewer than two-thirds (63%) of local jail jurisdictions conducted opioid use disorder (OUD) screenings at intake and more than half (54%) of jail jurisdictions provided inmates medications to treat opioid withdrawal (figure 1). Maruschak, Todd D.

Treatment 52

Treatment 52

Common Sense for Drug Policy Blog

NOVEMBER 29, 2023

Receipt of Opioid Use Disorder Treatments Prior to Fatal Overdoses and Comparison to No Treatment "The findings revealed that exposures to MOUD, even if not continued throughout the six-month exposure period was associated with reduced risk of a fatal poisoning compared to non-MOUD forms of treatment and no treatment exposure.

Treatment 52

Treatment Drugs 52

ASPET

JUNE 6, 2024

In keeping with NCCIH's natural product research priorities and in recognizing this gap in knowledge, NCCIH formally launched a research program in 2019 to expand research on the potential therapeutic benefit of minor cannabinoids and terpenes for the treatment of pain.

Research 100

Research Production Treatment 100

The Pharma Data

FEBRUARY 8, 2021

Janssen Announces Treatment with ERLEADA ® (apalutamide) Significantly Improved Overall Survival in Patients with Metastatic Castration-Sensitive Prostate Cancer. ERLEADA ® is an androgen receptor (AR) inhibitor indicated for the treatment of patients with nmCRPC and for the treatment of patients with mCSPC. 10 months. [5]

Treatment 52

Treatment Pharmaceutical Companies Therapies Pharmaceuticals 52

The Pharma Data

JANUARY 17, 2021

This coverage provides a minimally invasive treatment alternative for eligible patients. “Not being able to breathe really limits the ability of patients to go about their daily lives, and for those who qualify for the treatment, endobronchial valves can make a big difference.” 1354-1362, 2019.

Treatment 52

Treatment Clinical Trials Trials Disease 52

The Pharma Data

FEBRUARY 22, 2021

Efanesoctocog alfa, a novel and investigational factor VIII therapy independent of von Willebrand Factor, is designed to provide near-normal factor activity levels for the majority of the week in a once-weekly prophylactic treatment regimen. In 2019, Sobi’s revenues amounted to SEK 14.2

FDA 52

FDA Treatment Therapies International 52

Chemical Biology and Drug Design

OCTOBER 5, 2023

Aromatic aldehydes, which increase the oxygen affinity of human hemoglobin to prevent polymerization of sickle hemoglobin and inhibit red blood cell (RBC) sickling, have been the subject of keen interest for the development of effective treatment against SCD.

Metabolic Stability 100

Metabolic Stability Treatment Disease Research 100

Drug Target Review

AUGUST 29, 2024

However, these treatments will eventually fail for the majority of patients, so there is a strong need for better CAR therapies. How might the CD5 knockout approach impact the treatment of other types of cancers beyond T-cell lymphoma?

Therapies 59

Therapies Treatment Engineering Molecular Biology 59

Alta Sciences

APRIL 17, 2024

Five Promising Treatment Areas in Early-Phase Drug Development in 2024 aasimakopoulos Wed, 04/17/2024 - 15:52 Early-phase drug development is an ever-changing landscape, as emerging science leads to new promising areas of research for the treatment of human health issues.

Drug Development 52

Drug Development Treatment FDA Approval Drugs 52

Drug Target Review

JULY 9, 2024

Bowel cancer is the fourth most common cancer in the UK, accounting for 11 percent of all new cancer cases from 2017 to 2019 1 , and is the second most common cause of cancer death in the UK, accounting for 10 percent of all cancer deaths in the same time period. This study was published in Nature Genetics.

Regulations 105

Regulations DNA Treatment Research 105

Drug Target Review

MARCH 3, 2025

The search for effective treatments for neurodegenerative diseases like Parkinson’s disease has long been hindered by the brain’s complexity and the absence of adequate models for drug discovery. This approach has the potential to revolutionise clinical trial design and lead to more effective, personalised treatments.

Disease 52

Disease Treatment Therapies Cell Biology 52

Drug Target Review

OCTOBER 4, 2023

Antibody-drug conjugates (ADCs) have been a groundbreaking approach to cancer treatment with their ability to deliver cytotoxic drugs directly to diseased cells while sparing healthy tissues. Ultimately, flexibility in dual-payload ADC development means better treatments could reach patients sooner. Cancers 11 , 394 (2019).

Small Molecule 126

Small Molecule Drugs Immune Response Targeted Protein Degradation 126

The Pharma Data

MARCH 2, 2021

Boehringer Ingelheim and Gubra today announced a new research and licensing agreement focused on the identification and validation of targets and innovative peptide compounds for the treatment of obesity. iii Current treatment options have limited efficacy in terms of weight loss or are often associated with adverse events. “We

Treatment 52

Treatment Bioinformatics Clinical Development Therapies 52

Drug Target Review

DECEMBER 4, 2023

Tailoring medical care to a patient’s unique genetic makeup, alongside the close analysis of disease progression, leads to more effective treatments, reduced side effects and faster diagnoses. What’s more, it remains an open question as to whether our healthcare facilities are currently equipped to deliver such treatment programmes at scale.

Treatment 105

Treatment Science DNA Doctors 105

The Pharma Data

MAY 16, 2022

Food and Drug Administration (FDA) has lifted the clinical hold placed on the company’s Investigational New Drug Application (IND) to evaluate injectable lenacapavir for HIV treatment and HIV pre-exposure prophylaxis (PrEP). There is no cure for HIV or AIDS. About Lenacapavir.

Treatment 52

Treatment FDA Science Therapies 52

Chemical Biology and Drug Design

AUGUST 20, 2023

The binding mode of the docking complexes was simulated by the CB-Dock platform and Discovery Studio 2019 Client software. CCB might be an effective and interesting antimicrobial treatment strategy as CCB can potentially inhibit the growth of PA. These proteins were collected through the PDB and Uniprot platform.

Drugs 100

Drugs Treatment Research 100

National Institute on Drug Abuse: Nora's Blog

JULY 22, 2024

People with an opioid use disorder (OUD) urgently need treatment not just to protect them from overdosing but also to help them achieve recovery, but highly effective medications like buprenorphine and methadone remain underused. Almost all (99%) of those retained in treatment achieved remission.

Pharmacy 78

Pharmacy Treatment Community Pharmacies Trials 78

Drug Target Review

SEPTEMBER 4, 2023

Plants are not well exploited for the treatment of infectious agents, and inter-species biochemical processes and infectious agents habitat interaction are not well studied. 2019): CRISPR in Parasitology: Not Exactly Cut and Dried! 2019): Biological plasticity rescues target activity in CRISPR knockouts, Nature Methods.

Drugs 111

Drugs RNA DNA Disease 111

Broad Institute

JUNE 21, 2023

Now, researchers at the Broad Institute of MIT and Harvard have found that treatment with continuous hypoxia — low-oxygen conditions comparable to levels at a Mount Everest base camp — restores balance and coordination in a mouse model of Friedreich’s ataxia. A few treatments stood out.

Treatment 98

Treatment Disease Molecular Biology Medical Schools 98

Broad Institute

NOVEMBER 13, 2023

This commitment to the Gerstner Center for Cancer Diagnostics includes $10 million for current support for the Center and $10 million in endowed funding, adding to the $15 million originally committed by Gerstner and an initial endowment of $10 million from the Eli & Edythe Broad Foundation to establish the Center in 2019.

DNA 116

DNA Medical Schools Treatment Therapies 116

The Pharma Data

NOVEMBER 18, 2021

Eli Lilly and Company blazoned that registration is now open for the CHALLENGE-MIG clinical trial, the first and only head-to- head trial comparing twoanti-calcitonin gene- related peptide (CGRP) drugs for the preventative treatment of episodic migraine in grown-ups.1 gepants) may help people achieve the pretensions that count most to them.

Treatment 52

Treatment Clinical Trials Trials Disease 52

The Pharma Data

JANUARY 19, 2021

20, 2021 (GLOBE NEWSWIRE) — Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) announced today the submission of an Investigational New Drug (IND) to FDA for the investigational use of Tempol for the treatment of Coronavirus (COVID-19). SAN DIEGO, Jan. Dr. Dennis J. The company’s subsidiary, U.S.

Treatment 52

Treatment FDA Pharmaceuticals Government 52

Drug Target Review

SEPTEMBER 21, 2023

The findings supported the possibility put forward by Cotton et al (2016) concerning the chance of repurposing these drugs for adulticidal treatment. The available treatment for that is minor surgery -to remove the nodules. With accessible and effective treatments, this is feasible. doi: 10.1002/14651858.CD011146.pub2.

Drugs 105

Drugs Treatment Disease Research 105

The Pharma Data

SEPTEMBER 27, 2021

AbbVie Submits Regulatory Application to FDA for Risankizumab-rzaa (SKYRIZI®) for the Treatment of Patients 16 Years and Older with Moderate to Severe regional enteritis. 16,17 In April 2019, SKYRIZI received U.S. SKYRIZI was also approved by the ecu Commission in April 2019. ” In the analysis plans for the U.S.

Treatment 52

Treatment FDA Therapies Disease 52

The Pharma Data

MARCH 30, 2021

2] – The atogepant application demonstrates AbbVie’s longstanding commitment to providing multiple migraine treatment options, including BOTOX® (onabotulinumtoxinA), a preventive treatment for those with chronic migraine, and UBRELVY® (ubrogepant), an acute treatment for adults with migraine. .

Treatment 52

Treatment FDA Doctors Drugs 52

The Pharma Data

APRIL 3, 2021

Food and Drug Administration (FDA) has extended the review period for the supplemental New Drug Application (sNDA) for upadacitinib in the treatment of adults and adolescents with moderate to severe atopic dermatitis. In August 2019 , RINVOQ received U.S. vice chairman and president, AbbVie. About RINVOQ TM (upadacitinib).

Treatment 52

Treatment FDA Drugs Vaccine 52

Alta Sciences

MARCH 4, 2025

Despite having a final FDA guidance issued in 2017 , evolving drug development and treatment modalities continue to prompt important dialogue to adapt existing methods. One example is the recent interest in psychedelics for the treatment of psychiatric disorders, including major depressive disorder.

Clinical Trials 52

Clinical Trials FDA Drug Development Trials 52

Drug Target Review

NOVEMBER 8, 2023

Cell therapies hold immense promise for revolutionising the treatment of some of the most challenging diseases, but several technological and logistical hurdles stand in the way of unlocking their full potential. These patients typically fail frontline chemotherapies within 8 months of treatment and have few options for second line therapies.

Therapies 116

Therapies Engineering Treatment Molecular Biology 116

Drug Target Review

SEPTEMBER 25, 2024

4 Another related and well described non-oncogene resistance mechanism is the histological transformation of EGFR-mutated non-small cell lung cancer (NSCLC) to small-cell lung cancer upon treatment with an EGFR inhibitor. Notably, TT125-802 stabilised disease and prevented further outgrowth of tumours resistant to standard-of-care treatment.

Small Molecule 105

Small Molecule Therapies Regulations Treatment 105

The Pharma Data

MARCH 17, 2021

Food and Drug Administration (FDA) has extended the review period for the supplemental New Drug Application (sNDA) for upadacitinib in the treatment of adult patients with active psoriatic arthritis. In August 2019, RINVOQ received U.S. Have any signs or symptoms of blood clots during treatment with RINVOQ, including: Swelling.

Treatment 52

Treatment FDA Drugs Vaccine 52

The Pharma Data

MARCH 9, 2021

Ongoing Phase III studies in non-small cell lung cancer continue, evaluating canakinumab in earlier treatment settings. CANOPY-1 (NCT03631199) is a Phase III trial evaluating canakinumab as a first-line treatment for locally advanced or metastatic NSCLC in combination with pembrolizumab?and and platinum-based doublet chemotherapy 2.

Treatment 52

Treatment Immune Response Trials Clinical Trials 52

Drug Target Review

NOVEMBER 2, 2023

Epilepsy in Children: From Diagnosis to Treatment with Focus on Emergency. 2019 January 2 [2023 October 24];8(1):39. The scientists performed a genetic analysis of brain tissue, blood and buccal (epithelial) cells. Tissue samples were taken from six patients, aged two months to seven months, who underwent epilepsy surgery.

Hospitals 115

Hospitals Treatment Research Disease 115